Photo Credit: RDNE Stock project
Scientific Frontline: "At a Glance" Summary: Transcranial Magnetic Stimulation for PTSD
- Main Discovery: Transcranial magnetic stimulation effectively calms the amygdala, the brain's fear center, leading to a significant reduction in symptoms associated with post-traumatic stress disorder.
- Methodology: Investigators conducted a randomized, blinded clinical trial of fifty adults, utilizing magnetic resonance imaging to individually tailor the precise location for a two-week protocol of low-frequency transcranial magnetic stimulation compared to a placebo.
- Key Data: Seventy-four percent of individuals in the active treatment group experienced a clinically meaningful reduction in symptoms, with positive clinical outcomes sustained for at least six months post-treatment.
- Significance: This marks the first study to leverage magnetic resonance imaging to personalize brain stimulation for post-traumatic stress disorder, demonstrating that targeted neurobiological interventions yield measurable changes in brain function without requiring patients to recount trauma.
- Future Application: The methodology establishes a foundation for highly precise, individualized neurological treatments for post-traumatic stress disorder, expanding non-invasive therapeutic options for patients globally.
- Branch of Science: Psychiatry, Neuroscience, Behavioral Sciences.
- Additional Detail: Participants receiving the active treatment reported substantial shifts in how they emotionally processed their trauma, which included notable improvements in managing severe nightmares.
A study from the Emory University School of Medicine finds transcranial magnetic stimulation (TMS), a targeted form of non-invasive brain stimulation, can calm the brain’s fear center and significantly improve symptoms of post-traumatic stress disorder (PTSD), with benefits lasting months after treatment.
TMS is an FDA-approved treatment for several conditions including depression, though not for PTSD. It uses magnetic pulses to influence activity in specific brain regions. PTSD has been linked to heightened activity in the amygdala, the brain region involved in processing fear.
In this clinical trial, investigators in the Emory Department of Psychiatry and Behavioral Sciences examined whether two weeks of low-frequency TMS could reduce amygdala reactivity to threat and improve PTSD symptoms. They used MRI scans to precisely identify where on the head to apply stimulation, allowing the treatment to be personalized for each participant. The study was funded by the National Institutes of Health and the Brain and Behavior Research Foundation.
Fifty adults with PTSD symptoms enrolled in the study, and 47 completed it. Most participants were recruited through the Grady Trauma Project, a large-scale clinical research program studying civilian trauma based at Grady Health System and the Emory University School of Medicine. Participants were randomly assigned to receive either active TMS or a placebo treatment in a blinded design so they would not know which treatment they received. MRI scans measured amygdala responses to threat before and after treatment.
Researchers found that active TMS reduced right amygdala reactivity to threat. Participants who received active TMS showed significant improvement in PTSD symptoms. Clinical benefit was observed after just two weeks of treatment and lasting at least six months, the full period examined in the study. Seventy-four percent of individuals in the active TMS group experienced clinically meaningful symptom reduction.
“This study shows that we can directly target the brain circuits involved in PTSD and produce measurable changes in both brain function and symptoms,” says principal investigator Sanne van Rooij, PhD, associate professor of Psychiatry and Behavioral Sciences, Emory University School of Medicine. “By using MRI to guide stimulation, we are moving toward more precise, individualized treatments that address the biology of the disorder.”
Unlike traditional talk therapy, TMS treatment does not require patients to recount traumatic experiences, which may reduce a barrier to care for some people. Participants reported changes in how they emotionally experienced their trauma, including improved management of nightmares. Some described the treatment as “life changing,” saying it “gave me back my life.”
According to the researchers, this is the first study to use MRI scans to individualize TMS for PTSD. By demonstrating a specific change in the amygdala, a region known to function differently in PTSD, they say the findings advance understanding of the neurobiology of recovery and suggest a new direction for treatment of PTSD locally, nationally and internationally.
Funding: Grant support for the study included K01MH121653 and a NARSAD Young Investigator Award.
Published in journal: American Journal of Psychiatry
Authors: Sanne J.H. van Rooij, Ph.D., Ryan Langhinrichsen-Rohling, B.S., Sean T. Minton, B.A., Cecilia A. Hinojosa, Ph.D., Joshua Lukemire, Ph.D., Rebecca Lipschutz, Ph.D., Rebecca Hinrichs, M.A., Natalie Merrill, Ph.D., Timothy D. Ely, B.A., Kristina Dahlgren, Ph.D., Patlapa Sompolpong, B.A., Gregory Job, M.B.B.S., D.L.O., Patricio Riva-Posse, M.D., Paul E. Holtzheimer, M.D., Vince D. Calhoun, Ph.D., Joan A. Camprodon, M.D., Ph.D., Sheila A.M. Rauch, Ph.D., A.B.P.P., Nadine J. Kaslow, Ph.D., A.B.P.P., Kerry J. Ressler, M.D., Ph.D., Tanja Jovanovic, Ph.D., and William M. McDonald, M.D.
Source/Credit: Emory University
Reference Number: psyc040326_01
.jpg)